By integrating affibodies post-assembly through an oligonucleotide handle, CytoDirect achieved high specificity and enhanced cellular uptake in HER2-positive cancer cells, facilitating precise delivery of therapeutic oligonucleotides and doxorubicin [71]. Here, ERBB2 is linked to cancer.